ATE536156T1 - Vorrichtung zur dauerhaften in-vivo-freisetzung eines aktiven wirkstoffs - Google Patents

Vorrichtung zur dauerhaften in-vivo-freisetzung eines aktiven wirkstoffs

Info

Publication number
ATE536156T1
ATE536156T1 AT05824131T AT05824131T ATE536156T1 AT E536156 T1 ATE536156 T1 AT E536156T1 AT 05824131 T AT05824131 T AT 05824131T AT 05824131 T AT05824131 T AT 05824131T AT E536156 T1 ATE536156 T1 AT E536156T1
Authority
AT
Austria
Prior art keywords
sustained
release
active agent
active ingredient
vivo release
Prior art date
Application number
AT05824131T
Other languages
English (en)
Inventor
John Higuchi
S Li
William Higuchi
Daniel Mufson
Michael Delmage
Anthony Tuitupou
Rajan Kochambilli
Original Assignee
Aciont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciont Inc filed Critical Aciont Inc
Application granted granted Critical
Publication of ATE536156T1 publication Critical patent/ATE536156T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05824131T 2004-10-27 2005-10-27 Vorrichtung zur dauerhaften in-vivo-freisetzung eines aktiven wirkstoffs ATE536156T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62315004P 2004-10-27 2004-10-27
US11/238,104 US20060089590A1 (en) 2004-10-27 2005-09-27 Methods and devices for sustained in-vivo release of an active agent
US11/238,144 US8246949B2 (en) 2004-10-27 2005-09-27 Methods and devices for sustained in-vivo release of an active agent
PCT/US2005/039672 WO2006047788A2 (en) 2004-10-27 2005-10-27 Methods and devices for sustained in-vivo release of an active agent

Publications (1)

Publication Number Publication Date
ATE536156T1 true ATE536156T1 (de) 2011-12-15

Family

ID=36228523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05824131T ATE536156T1 (de) 2004-10-27 2005-10-27 Vorrichtung zur dauerhaften in-vivo-freisetzung eines aktiven wirkstoffs

Country Status (8)

Country Link
US (4) US20060089590A1 (de)
EP (1) EP1807149B1 (de)
JP (1) JP2008518038A (de)
KR (1) KR20070090893A (de)
AT (1) ATE536156T1 (de)
AU (1) AU2005299601A1 (de)
CA (1) CA2586536A1 (de)
WO (1) WO2006047788A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1965856A2 (de) 2005-12-30 2008-09-10 Tti Ellebeau, Inc. Iontophoretische systeme, vorrichtungen und verfahren zur abgabe von wirkstoffen an eine biologische schnittstelle
US8923961B2 (en) 2006-10-18 2014-12-30 The Cleveland Clinic Foundation Electrode assembly for delivering a therapeutic agent into ocular tissue
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
CA2674075C (en) * 2006-12-29 2012-10-30 Charles P. Theuer Antifolate agent combinations in the treatment of cancer
WO2008087803A1 (ja) * 2007-01-16 2008-07-24 Hokkaido University 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
US10398594B2 (en) * 2007-10-04 2019-09-03 Aciont, Inc. Intrascleral drug delivery device and associated methods
US8480638B2 (en) * 2007-10-04 2013-07-09 Aciont, Inc. Intraocular iontophoretic device and associated methods
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20090143752A1 (en) * 2007-12-03 2009-06-04 Higuchi John W Passive intraocular drug delivery devices and associated methods
RU2481842C2 (ru) 2008-03-11 2013-05-20 Алькон Рисерч, Лтд. Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
WO2010036966A1 (en) * 2008-09-26 2010-04-01 The Cleveland Clinic Foundation Apparatus and method for delivering a therapeutic agent to ocular tissue
US20110281834A1 (en) * 2008-11-10 2011-11-17 Friden Phillip M Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2011005879A2 (en) * 2009-07-09 2011-01-13 Incube Labs, Llc Ring electrode assembly and applications thereof
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
KR20140022783A (ko) * 2010-12-22 2014-02-25 데이고꾸세이약꾸가부시끼가이샤 이온 도입 치료법에 사용되는 전극 패드
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013029033A2 (en) * 2011-08-25 2013-02-28 Brian Pulliam Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
WO2014004845A1 (en) * 2012-06-29 2014-01-03 Johnson & Johnson Vision Care, Inc. Method and ophthalmic device for galvanic healing of an eye
JP5580383B2 (ja) * 2012-10-05 2014-08-27 株式会社 資生堂 美容機器及び通電方法及び記録媒体
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
ES2672327T3 (es) * 2014-01-27 2018-06-13 Opia Technologies Dispositivo de iontoforesis ocular
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
KR20170046146A (ko) * 2014-08-13 2017-04-28 더 존스 홉킨스 유니버시티 각막 동종이식 거부 및 신혈관 형성의 예방을 위한 글루코 코르티코이드-로딩된 나노입자
JP2018502639A (ja) * 2015-01-22 2018-02-01 アイゲート ファーマスーティカルズ，インコーポレイテッド イオントフォレシスコンタクトレンズ
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3414330A4 (de) * 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. Zusammensetzungen mit verbesserter intravitrealer halbwertzeit und verwendungen dafür
US20190125669A1 (en) * 2016-04-17 2019-05-02 Children's Medical Center Corporation Systems and methods for steroidal gels
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
MX2019006863A (es) 2016-12-13 2019-09-13 Beta Therapeutics Pty Ltd Inhibidores de heparanasa y uso de los mismos.
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
WO2020028829A1 (en) * 2018-08-02 2020-02-06 University Of Florida Research Foundation Methods and compositions for iontophoretic drug delivery to the eye
EP3909056B1 (de) 2019-01-09 2025-05-21 Verily Life Sciences LLC Abgabe eines programmierbaren therapeutikums aus einer am auge montierten vorrichtung
WO2020146362A1 (en) 2019-01-09 2020-07-16 Verily Life Sciences Llc Eye mounted device for therapeutic agent release
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605536A (en) * 1983-08-18 1997-02-25 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
US4627879A (en) * 1984-09-07 1986-12-09 The Trustees Of Columbia University In The City Of New York Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma
US4738850A (en) * 1986-05-27 1988-04-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US5496266A (en) * 1990-04-30 1996-03-05 Alza Corporation Device and method of iontophoretic drug delivery
IT1244030B (it) 1989-12-21 1994-06-28 Elan Corp Plc Dispostitivo in due parti per la somministrazione controllata di un ingrediente
US5302172A (en) * 1990-03-15 1994-04-12 North Carolina State University Method and composition for iontophoresis
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5246417A (en) * 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6189538B1 (en) * 1995-11-20 2001-02-20 Patricia E. Thorpe Tourniquet and method of using
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
IL123290A (en) * 1998-02-13 2001-12-23 Hadasit Med Res Service Iontophoretic device
JP3600158B2 (ja) * 1998-05-13 2004-12-08 シグナス， インコーポレイテッド 生理学的分析物のモニタリング
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
US6424862B1 (en) 1999-02-10 2002-07-23 Gmp Drug Delivery, Inc. Iontophoresis electroporation and combination patches for local drug delivery to body tissues
US6319240B1 (en) * 1999-05-25 2001-11-20 Iomed, Inc. Methods and apparatus for ocular iontophoresis
US6539251B2 (en) * 1999-05-25 2003-03-25 Iomed, Inc. Ocular iontophoretic apparatus
US7124088B2 (en) * 1999-07-30 2006-10-17 Progressive Casualty Insurance Company Apparatus for internet on-line insurance policy service
US6394994B1 (en) * 1999-08-27 2002-05-28 Vyteris, Inc. Method for testing the ability of an iontophoretic reservoir-electrode to deliver a medicament
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
JP3677421B2 (ja) 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
US6540230B1 (en) * 2000-05-04 2003-04-01 Walker Digital, Llc Method and apparatus for playing a card game including a bust insurance option
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6579276B2 (en) * 2001-01-22 2003-06-17 Iomed, Inc. Ocular iontophoretic device and method for inhibiting vascular endothelial growth factor (VEGF) using the same
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US20020107503A1 (en) * 2001-02-06 2002-08-08 Gordon Lucas S. Intermittent drug delivery method and system
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
FR2830767B1 (fr) 2001-10-12 2004-03-12 Optis France Sa Dispositif de delivrance de medicaments par iontophorese ou electroporation introculaire
FR2830766B1 (fr) 2001-10-12 2004-03-12 Optis France Sa Dispositif de delivrance de medicaments par iontophorese transpalpebrale
US7349733B2 (en) 2001-11-02 2008-03-25 Ceramatel, Inc. Iontophoretic drug delivery systems
AU2003224099B2 (en) * 2002-04-19 2006-11-09 Novartis Ag Novel biomaterials, their preparation and use
US7785578B2 (en) * 2002-10-11 2010-08-31 Aciont, Inc. Non-invasive ocular drug delivery
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
JP4104447B2 (ja) * 2002-12-16 2008-06-18 新光電気工業株式会社 燃料電池
US7729946B2 (en) * 2003-01-24 2010-06-01 Massive Incorporated Online game advertising system
US20040167459A1 (en) * 2003-02-21 2004-08-26 Higuchi William I. Methods and systems for controlling and/or increasing iontophoretic flux
FR2855761B1 (fr) 2003-06-03 2006-02-24 Optis France Sa Dispositif oculaire de delivrance variable de principes actifs par iontophorese
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
WO2006014484A2 (en) 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions

Also Published As

Publication number Publication date
JP2008518038A (ja) 2008-05-29
AU2005299601A1 (en) 2006-05-04
US20060089590A1 (en) 2006-04-27
WO2006047788A3 (en) 2009-05-07
WO2006047788A2 (en) 2006-05-04
US20080009471A1 (en) 2008-01-10
EP1807149B1 (de) 2011-12-07
EP1807149A2 (de) 2007-07-18
US8246949B2 (en) 2012-08-21
US20120201800A1 (en) 2012-08-09
KR20070090893A (ko) 2007-09-06
EP1807149A4 (de) 2010-06-16
US20060088515A1 (en) 2006-04-27
CA2586536A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2006047788A3 (en) Methods and devices for sustained in-vivo release of an active agent
IL273422A (en) Methods and systems for extracorporeal organ treatment
WO2009152276A3 (en) Photoacid generators and lithographic resists comprising the same
ATE489048T1 (de) Vorrichtung für kombinierte behandlung
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
UA93910C2 (ru) Алкоксиалкилзамещенные циклические кетоэнолы и средство для борьбы c вредителями
MX2009004365A (es) Dispositivos oculares y metodos para la fabricacion y uso de los mismos.
DE602005002066D1 (de) Vorrichtung zur Abschätzung des Hautzustandes
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
TW200735773A (en) Insecticidal compositions with improved activity
EP2010946A4 (de) Mikrostrukturierte artikel mit einem stickstoffhaltigen inhaltsstoff
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
MX2010004198A (es) Un identificador de oreja para marcar un animal y para tomar muestras de tejido de dicho animal.
WO2007019554A3 (en) Polysaccharides for delivery of active agents
MX2013012696A (es) Metodo y composicion para tratamiento de semillas.
CO6251376A2 (es) Triazolilpiridina cetonas herbicidas
EP2543586A4 (de) Schnell und ohne werkzeug abnehmbare pedalvorrichtung
GB2467065A (en) Bait station
NO20071636L (no) Flytende allergivaksineformulering for oromukosal administrering
ATE492271T1 (de) Verfahren zur herstellung eines hydroxystilben- haltigen drogenextraktes
ATE528038T1 (de) Vorrichtung zur gesteuerten freisetzung chemischer moleküle
TW200640446A (en) Prophylactic anti-stress agent
DE602007009413D1 (de) Sitamaquintosylat zur behandlung von leishmaniase
NZ547846A (en) Use of goat serum for veterinary treatment
UA51142U (ru) Способ оценки токсичности дезинфицирующего препарата с использованием инфузории тетрахимены пириформис